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IgM in human immunity to Plasmodium falciparum malaria
M. J. Boyle1,2,3*†, J. A. Chan1, I. Handayuni2, L. Reiling1, G. Feng1,4, A. Hilton1, L. Kurtovic1,5, 
D. Oyong2,6, K. A. Piera2, B. E. Barber2,3,7, T. William7,8, D. P. Eisen9, G. Minigo2,6, C. Langer1, 
D. R. Drew1, F. de Labastida Rivera3, F. H. Amante3, T. N. Williams10,11, S. Kinyanjui10,12, K. Marsh10,12, 
D. L. Doolan9, C. Engwerda3, F. J. I. Fowkes1,13,14, M. J. Grigg2,7, I. Mueller15,16,17, J. S. McCarthy3,18,  
N. M. Anstey2,6, J. G. Beeson1,4,19*
Most studies on human immunity to malaria have focused on the roles of immunoglobulin G (IgG), whereas the 
roles of IgM remain undefined. Analyzing multiple human cohorts to assess the dynamics of malaria-specific IgM 
during experimentally induced and naturally acquired malaria, we identified IgM activity against blood-stage 
parasites. We found that merozoite-specific IgM appears rapidly in Plasmodium falciparum infection and is prominent 
during malaria in children and adults with lifetime exposure, together with IgG. Unexpectedly, IgM persisted for 
extended periods of time; we found no difference in decay of merozoite-specific IgM over time compared to that of 
IgG. IgM blocked merozoite invasion of red blood cells in a complement-dependent manner. IgM was also associated 
with significantly reduced risk of clinical malaria in a longitudinal cohort of children. These findings suggest that 
merozoite-specific IgM is an important functional and long-lived antibody response targeting blood-stage malaria 
parasites that contributes to malaria immunity.
INTRODUCTION
With the stagnation of reduction in malaria over the past 3 to 5 years 
despite ongoing global control efforts (1), development of new tools and 
effective vaccines for malaria control is strongly needed. The most ad-
vanced malaria vaccine, RTS,S, based on the pre-erythrocytic sporozoite 
stage, had only 26 to 36% efficacy in infants and young children re-
ceiving a booster dose (2). An important target of vaccine development 
is the blood stage of Plasmodium falciparum, where vaccines aim to 
prevent merozoite invasion of red blood cells (RBCs) (3). Antibodies 
against merozoites act to suppress parasite blood-stage replication and 
disease through multiple mechanisms, including direct inhibition of 
erythrocyte invasion, interactions with complement to lyse merozoites 
and inhibit invasion, and interactions with Fc receptors to promote 
phagocytosis (3). The overwhelming majority of research on protective 
human antibodies that target the merozoite has focused on the role of 
immunoglobulin G (IgG). In contrast, the potential importance of IgM 
in protective immunity has received comparatively limited attention, 
and much less is known about the dynamics of IgM acquisition and 
maintenance in malaria or how IgM might mediate protective effects.
The general view of IgM responses is that IgM is induced early 
by infection but then rapidly decays and is “replaced” by IgG after 
several weeks and in memory phase immunity. This paradigm of early 
IgM induction followed by conversion to IgG has been demonstrated 
in human responses to multiple infections including dengue (4), West 
Nile virus (5), and HIV (6), among others. However, this dynamic 
has not been established for P. falciparum malaria in humans, and 
relatively abundant levels of malaria-specific IgM have been reported 
in some studies of populations with high malaria exposure (7–9). 
Furthermore, the existence of P. falciparum–specific IgM memory 
B cells was recently demonstrated in samples from naturally exposed 
human subjects and mouse models of malaria (10). We hypothesized 
that the induction and maintenance of IgM responses to malaria may 
not follow the typical profile seen in other diseases and animal models 
and that IgM may have an important role in immunity to P. falciparum 
not only in primary infection but also during subsequent infections.
Here, we define the acquisition, maintenance, and decay of 
merozoite-specific IgM during P. falciparum infection and clinical 
malaria in humans in clinical trials of experimental blood-stage malaria 
infection in naïve individuals and among cohorts of naturally exposed 
individuals with differing levels of malaria exposure, including children 
and adults. We provide evidence that specific IgM not only is rapidly 
induced following a primary P. falciparum infection in malaria- naïve 
adults but also is prominent in most patients during malaria disease and 
P. falciparum infection in both children and adults with lifetime malaria 
exposures in endemic areas of Sabah, Malaysian Borneo, and Papua New 
Guinea (PNG). Further, IgM was a long-lived response in the absence 
of reinfection. To provide a mechanistic link to immunity, we demon-
strate that IgM can inhibit merozoite invasion of RBCs and blood-stage 
replication by the fixation and activation of complement on the surface 
of merozoites. IgM to the merozoite surface increased with age and was 
associated with protection in a longitudinal cohort of naturally exposed 
children. Our data suggest that IgM responses, alongside IgG, are 
important contributors to naturally-acquired immunity against malaria.
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RESULTS
Merozoite-specific IgM is rapidly induced during a low-dose 
primary P. falciparum infection
To investigate the induction of specific IgM in a first malaria infection, 
we assessed the kinetics of malaria-specific antibodies acquired in re-
sponse to blood-stage controlled human malaria infection (CHMI) in 
naïve Australian adults (11). Subjects were infected with blood-stage 
P. falciparum and treated when blood parasite levels reached 20,000 
(1050 to 107,980) parasites/ml [median (minimum to maximum); 
Fig. 1A]. In this experimental human model, we recently showed 
that IgM against a number of merozoite surface antigens is detect-
able a month after parasite infection (12). Here, we measured IgM 
and IgG levels in serum samples collected from participants to three 
merozoite vaccine candidates (MSP2, AMA1, and EBA175) at days 7 
(day of treatment), 14, and 30 following P. falciparum inoculation and 
standardized responses compared to pooled immune adult PNG sera. 
While there was limited background reactivity of IgM before inocula-
tion (day 0), there was clear evidence for the induction of antigen- 
specific IgM between 14 and 30 days after inoculation, indicated by 
large increases in antibody reactivity (Fig. 1B). There was no evidence 
for IgM or IgG induction at day 7 (day of treatment), indicating that 
induced antibodies likely had little role in parasite clearance following 
drug treatment. To confirm that increased IgM was due to a specific 
IgM response and not due to a global increase in nonimmune IgM, 
we tested for IgM reactivity to a nonmalarial protein before and fol-
lowing CHMI; there was no evidence for increased nonimmune IgM 
reactivity (fig. S1A). There was also a significant induction of IgG to 
MSP2 by 30 days. There was a significantly higher proportion of pos-
itive IgM responses compared to IgG responses by day 30 (table S1). 
To assess the relative breadth of IgM and IgG following controlled 
human P. falciparum infection, antibodies were quantified against a 
panel of merozoite surface proteins at 30 days following parasite in-
oculation in a second group of volunteers. Overall, there was a sig-
nificant detection of IgM against all eight antigens tested (MSP1, 
MSP2, MSP3, MSP4, MSP5, MSP6, PfRh2, and EBA181) but only a 
significant detection of IgG to four of these antigens (MSP1, MSP2, 
MSP3, and MSP5; fig. S1, B and C). There was a higher prevalence of 
seropositive of IgM responses to MSP1, MSP4, and MSP6 compared 
to IgG (Fig. 1C). Similarly, the magnitude of antibody induction above 
background levels (arbitrary units) appeared greater for IgM than 
IgG for MSP1, MSP4, and MSP6 but not other antigens (Fig. 1D). 
However, caution should be taken when comparing magnitudes of 
responses for IgG versus IgM because of possible differences in sen-
sitivity of secondary detection antibodies. We explored the avidity 
of IgM and IgG to MSP2 among a subset of samples and found that 
avidity was higher for IgM than for IgG (Fig. 1E). We studied anti-
bodies to MSP2 because this was a prominent response observed in 
CHMI (Fig. 1B).
Merozoite-specific IgM appears prominent in clinical malaria 
and has similar kinetics to IgG following infection
We next quantified the induction and waning of IgM during a malaria 
clinical episode in children and adults in a malaria-endemic region 
of Sabah, Malaysian Borneo, who had a lifetime exposure to malaria 
infection (table S2). We tested serum samples for specific IgM to intact 
merozoites and recombinant MSP2. We also measured cytophilic 
IgG subclass responses, IgG1 and IgG3, that are associated with pro-
tection from malaria (3). During clinical malaria, a higher proportion 
of patients was IgM seropositive and had a higher magnitude of IgM 
compared to uninfected healthy community controls for merozoites 
and MSP2 [merozoites: prevalence, 80% versus 26% (P < 0.0001) and 
magnitude median optical density (OD), 1.17 versus 0.2 (P < 0.0001); 
MSP2: prevalence, 76% versus 18% (P < 0.0001) and magnitude median 
OD, 1.24 versus 0.11 (P < 0.0001) Fig. 2, A and B]. There was no 
difference in IgM seropositivity (80%) compared to IgG1 (82%) or IgG3 
(82%), suggesting that, by the time symptomatic disease develops, both 
IgM and IgG responses have been established in populations with 
prior malaria exposure (Fig. 2, A and B). In a subset of patients, sera 
were available at days 7 and/or 28 following treatment. Among these, 
there was a significant increase in IgM levels to intact merozoites 
and MSP2 at 7 days following treatment, which reduced to levels seen 
during clinical malaria by 28 days following treatment. There was 
no apparent difference in the pattern of induction and decline of IgM 
compared to IgG1 and IgG3 subclasses (Fig. 2, C and D, and fig. S2, 
A and B). When patients were divided into children (<15 years old) 
and adults, reflecting different levels of cumulative malaria exposure, 
there was no difference in rates of seroprevalance of IgM or IgG sub-
classes to intact merozoites. For MSP2 responses, there was a signifi-
cantly higher prevalence of IgM and IgG1, but lower prevalence of 
IgG3, in children compared to adults [89% versus 68% (P < 0.0001) 
for IgM and IgG1, respectively, and 73% versus 81% (P = 0.006) for 
IgG3; fig. S2C]. Children also had slightly higher magnitude of IgM 
to the merozoite surface (P = 0.04) but not to MSP2 during clinical 
malaria (P = 0.63; fig. S2, D and E). The higher IgM in children was 
not apparent following treatment (fig. S2, D and E). In avidity assays 
among a subset of samples, the avidity of IgG was higher than that 
of IgM (Fig. 2E) and appeared higher than the IgG avidity observed 
in the CHMI studies.
Merozoite-specific IgM is maintained for at least 12 months 
following P. falciparum malaria
To quantify IgM kinetics over a longer duration after infection, we 
assessed IgM and IgG levels in serum samples collected from indi-
viduals living in a malaria-endemic region of Kenya (Ngerenya, Kilifi 
District) at three time points during a period of rapidly declining 
malaria transmission intensity (13). We examined IgM and IgG anti-
bodies to MSP2 among a subset of children who had no recorded 
episode of parasitemia between October 2003 and October 2004. 
We found that 70% of children had detectable IgM to MSP2 in 
 October 2003, and prevalence was not significantly different to IgG 
(IgG prevalence, 82%; P = 0.16). IgM and IgG responses were weakly 
correlated (rho = 0.386, P = 0.006). There was no change in IgM or 
IgG prevalence rates between October 2003 and October 2004 
(Fig. 3A). There was no overall change in the magnitude of IgM 
responses over time (P = 0.83), but there was a significant decline in 
IgG magnitudes between October 2003 and May 2004 (P = 0.004; 
Fig. 3B).
Longevity of IgM was also observed in serum samples in returned 
travelers who were residents of Australia, with no prior malaria epi-
sodes, who acquired malaria while traveling; in this cohort, we could 
exclude any potential reinfection that could influence antibody kinetics 
during follow-up (table S3). At the time of clinical malaria, both IgG 
and IgM were detected (Fig. 3C). In the year following clinical malaria, 
there was no apparent difference in IgG and IgM decay within indi-
viduals. Even 6 months after malaria, detectable levels of IgM but not 
IgG were still present in all returned travelers’ serum samples tested 
(Fig. 3D). To compare the overall loss of antibodies, the change in 
antibody levels was calculated at two time points following clinical 
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Fig. 1. Induction of IgM and IgG following controlled human P. falciparum infection. (A) Malaria-naïve healthy individuals underwent inoculation with 1800 or 
2800 viable P. falciparum 3D7-parasitized RBCs, and peripheral parasitemia was measured by qPCR. Participants were treated with anti-malarial drugs at day 7 or 8 of 
infection. Blood samples from 60 volunteers (from 10 independent cohorts) were collected before infection (day 0), at peak infection (day 7 or 8), and 14 or 15 and 28 to 36 days 
after inoculation; in analysis, these time points are grouped as days 0, 7, 14, and 30. Data are representative of 10 individuals from four cohorts. (B) IgM and IgG levels were 
measured against MSP2, AMA1, and EBA175 (RII) at days 0, 7, 14, and 30 following controlled human P. falciparum infection in malaria-naïve adults (n = 40). Antibody responses 
are expressed as optical density (OD) after background subtraction of no-serum wells. Positivity threshold was calculated as means + 3SDs of responses at day 0 (dotted 
line). P values are Wilcoxon matched-pairs signed-rank test. (C) IgM and IgG responses to several merozoite antigens were measured at day 30 following infection in CHMI 
participants (n = 20). Prevalence of antibody responses was considered as a positive response if antibody levels were greater than means + 3SDs of responses at day 0. 
Data are proportion positive, and error bars are upper 95% confidence interval calculated by the Wald method. P value is calculated by Fisher’s exact test. (D) Magnitude 
of responses relative to day 0 was assessed as arbitrary units (AU = OD day 30/means + 3SDs of responses at day 0). P values are Wilcoxon matched-pairs signed-rank test. 
(E) Affinity of IgM and IgG to MSP2 was assessed by the dissociation of antibodies using increasing concentrations of ammonium thiocynate. Data are means ± SEM of 
eight individuals tested in two assays in duplicate, expressed as the percentage of OD in PBS. P values indicate Sidak’s multiple comparison test of IgM verses IgG from 
two-way analysis of variance (ANOVA), taking into account repeat measures for each individual (*P < 0.05 and **P < 0.01).
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malaria, between 30 and 60 days or between 180 and 300 days. There 
was no difference in the change in IgM compared to IgG at either 
time points, indicating that IgM was not more rapidly lost than IgG 
following malaria (Fig. 3E).
IgM inhibits merozoite invasion via complement  
fixation and activation
We recently demonstrated that a key functional mechanism of 
merozoite- specific IgG is complement fixation (14). We found that 
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Fig. 2. Induction and waning kinetics of merozoite-specific IgM during naturally acquired P. falciparum malaria. (A and B) IgM, IgG1, and IgG3 binding to intact 
merozoites (A) and recombinant MSP2 (B) was assessed among individuals with clinical malaria (n = 50) and uninfected endemic community controls (n = 30) in individuals 
in Sabah, Malaysian Borneo. Antibody reactivity is shown as seroprevalence and media [plus interquartile range (+IQR)] OD. Seroprevalence (left) was calculated using a 
cutoff defined as the mean OD + 3SDs of unexposed Australian naïve controls. (C and D) IgM, IgG1, and IgG3 binding to intact merozoites (C) and recombinant MSP2 (D) 
was assessed in patients with clinical malaria in Sabah, Malaysian Borneo, and at 7 (n = 26) and 28 days (n = 32) after anti-malarial treatment. Solid lines and gray area are 
generated from LOWESS smooth calculations in R software. Raw data are indicated as points. (E) Affinity of IgM and IgG to MSP2 was assessed by the dissociation of anti-
bodies using increasing concentrations of ammonium thiocynate. Data are means ± SEM of eight individuals tested in two assays in duplicate, expressed as the percentage of 
OD in PBS. P values indicate Sidak’s multiple comparison test of IgM versus IgG from two-way ANOVA, taking into account repeat measures for each individual 
(**P < 0.01 and ***P < 0.001).
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IgG interacted with the first component of the classical complement 
cascade, C1q, to directly inhibit RBC invasion (in the absence of 
other complement components) and to fix complement on the 
merozoite surface, leading to lysis (14). IgM is also known to bind 
C1q and activate the classical complement pathway. To assess the 
capacity of IgM to target merozoites via complement fixation, we 
separated IgM and IgG fractions from serum pooled from patients 
within our Sabah cohort using protein G columns. Bound fractions 
contained IgG, while unbound IgG-depleted fractions contained 
IgM and are referred herein as “IgM fractions” for clarity of reading. 
The purity of IgG and IgM fractions was assessed via enzyme-linked 
immunosorbent assay (ELISA) and Western blot. There was minimal 
IgM in the IgG fraction and no remaining IgG detectable in the IgM 
fraction (fig. S3, A to C). IgM and IgG fractions at 50 g/ml were 
tested in established invasion inhibition assays with isolated mero-
zoites (15). Both IgM and IgG fractions from malaria-exposed indi-
viduals effectively inhibited merozoite invasion in the presence of 
normal nonimmune serum (complement active) (Fig. 4A). There was 
no evidence that IgM or IgG fractions directly inhibited merozoite 
invasion in the absence of active complement, as invasion was com-
parable to naïve antibody samples when tested in heat-inactivated 
serum (complement inactive) (Fig. 4A).
To further support the role of complement in IgM inhibitory 
activity, we demonstrated that IgM could fix and activate complement 
on intact merozoites and MSP2. Levels of C1q (the primary component 
of the classical complement cascade), and downstream components 
C3b and C5b-C9 (which form the membrane attack complex in the 
cell surface to mediate lysis), were quantified. Both IgM and IgG 
fractions effectively fixed C1q, leading to the formation of C3b and 
C5b-C9 on the surface of the merozoite and on recombinant MSP2 
(Fig. 4B). On intact merozoites, the level of C1q fixation was two-
fold higher with IgG compared to IgM. However, it was notable that 
the level of C3b and C5b-C9 deposition was ninefold higher with 
IgM compared to IgG fractions; relative to the level of C1q fixation, 
C5b-C9 formation was ~20-fold higher for IgM. Similar patterns of 
C1q, C3b, and C5b-C9 deposition were seen with recombinant MSP2 
(Fig. 4B). This suggests that IgM is substantially more effective at 
activating the complement cascade to promote C5b-C9 formation. 
This high activity is despite lower avidity of IgM compared to IgG 
(fig. S3D). Supporting the high complement-fixing capacity of IgM, 
we observed that IgM and complement promoted merozoite lysis 
more efficiently than IgG, reflecting the formation of membrane 
attack complex and its effects on merozoites (fig. S4). To confirm that 
complement activation was occurring via the classical complement 
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Fig. 3. Maintenance of P. falciparum specific IgM and IgG. (A and B) IgM and IgG binding to recombinant MSP2 was measured in children from Ngerenya, Kenya who 
had no detectable parasite infection in October 2003, May 2004, and October 2004, during a period of rapidly declining transmission (n = 50). (A) IgM and IgG prevalence 
at the three time points (seropositive defined as greater than means + 3SDs of reactivity of malaria-naïve donors). P is Chi-square test. (B) Magnitudes of IgM and IgG re-
activity over three time points. P value is calculated by nonparametric ANOVA and Friedman test. Dotted line indicates positive threshold calculated from means + 3SDs 
of reactivity of malaria-naïve donors. (C) IgM and IgG binding to recombinant MSP2 during clinical malaria in Australian returned travelers (n = 10). Dotted line indicates 
the seropositive threshold. (D) Magnitudes of IgM and IgG were measured at different time points following acute illness and treatment (n = 10). Colored lines correspond 
to different individuals. Dotted line indicates seropositive threshold. (E) There was no significant difference in the change in IgG and IgM levels at 30 to 60 days (n = 8) or 
between 180 to 300 days (n = 5) after disease compared to clinical time point (measured 0 to 7 days following treatment). Dotted line indicates no change. P values were 
calculated using the Wilcoxon matched-pairs signed-rank test.
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cascade, complement activation on MSP2 by IgM and IgG was  assessed 
using C1q-depleted sera. There was minimal formation of comple-
ment components C3b and C5b-C9 for both IgG and IgM fractions 
using C1q-depleted sera. Deposition of C3b and C5b-C9 was regained 
with the reconstitution of depleted sera with C1q (Fig. 4C).
Relationship between complement fixation, IgM, and IgG
We have recently shown that the capacity of antibodies to fix com-
plement to specific merozoite antigens is strongly associated with 
protection (16). To investigate the relative importance in IgM in 
complement-dependent immunity targeting the merozoite, we 
 assessed the relationship between IgM, IgG1, and IgG3 subclass anti-
bodies and C1q-fixing antibody activity to purified merozoites using 
serum samples from patients with a clinical malaria episode in Sabah. 
Magnitudes of C1q-fixing antibodies were tightly correlated with 
formation of downstream complement components C3b and C5b-C9 
(fig. S5A) (16). Similar to antibody responses (Fig. 2A), the prevalence 
and magnitude of C1q-fixing antibodies were higher in participants 
with clinical malaria compared to healthy endemic controls [prevalence, 
73% versus 6% (P < 0.0001); median OD, 0.94 versus 0.2 (P < 0.0001); 
fig. S5, B and C]. The proportion or magnitude of C1q-fixing anti-
bodies was not different between adults and children during clinical 
malaria (fig. S5, D and E). Levels of C1q-fixing antibodies significantly 
correlated with IgM responses (rho = 0.45, P = 0.001). There was 
also a strong correlation between IgG1 and IgG3 with C1q, reflect-
ing a substantial contribution of these IgG subclass in mediating 
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Fig. 4. Merozoite-specific IgM inhibits invasion in a complement-dependent manner. (A) Isolated IgM and IgG fractions at 50 g/ml from malaria-exposed donors 
(Sabah, Malaysian Borneo) or naïve donors (Australia) were tested in merozoite invasion inhibition assays (at 50 g/ml) with normal serum (NS) or heat-inactivated serum 
(HIS) from malaria-naïve donors as a source of complement. Data are expressed as the percentage of invasion in heat-inactivated serum, with no antibody control. Data 
are means ± SD of two assays performed in duplicate. Significant differences are indicated as P < 0.05 by Mann-Whitney U test. *P < 0.05. (B) Isolated IgM and IgG fractions were 
tested for deposition of complement components (C1q, C3b, and C5b-C9) on intact merozoites or recombinant MSP2 by ELISA with 10% normal sera from malaria-naïve 
donors as a source of complement. Data represent the level of complement binding measured in OD values minus deposition observed using naïve IgM and IgG. (C) IgM 
and IgG fractions were tested for deposition of complement components on recombinant MSP2 by ELISA with 10% C1q-depleted sera and C1q-depleted sera reconstituted 
with purified C1q (10 g/ml). Data are means ± SEM of two independent assays performed in duplicate. (D) The level of C1q-fixing antibodies and IgM and IgG1/IgG3 
isotypes to merozoites was quantified in 50 individuals with a clinical malaria episode from Sabah. IgM, IgG1, and IgG3 were correlated with C1q fixation. (E) To compare 
directly between C1q fixation and IgM or IgG1/IgG3, antibody levels were converted to arbitrary units (the percentage of the highest measured response within cohort) 
and ranked according to levels of C1q fixation. In some individuals with relatively high C1q-fixing antibodies (defined as >40% of highest responder), IgM dominated the 
antibody response targeting the merozoite.
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C1q fixation (for both IgG1 and IgG3, rho = 0.91, P < 0.0001; Fig. 4D). 
However, 30% of individuals (15 of 50) were identified with relatively 
high C1q-fixing antibodies but relatively low levels of IgG1 and IgG3 
(Fig. 4E), suggesting that, in the absence of IgG complement-fixing 
subclasses, IgM responses were important in mediating C1q fixation 
to P. falciparum.
Merozoite-specific IgM is associated with protection 
from malaria in naturally exposed children
To investigate the potential importance of IgM alongside IgG in 
protection from malaria, we measured IgM and IgG levels in plasma 
samples against intact merozoites in 199 children (5 to 14 years old) 
from a longitudinal cohort in a moderate-to-high malaria transmis-
sion region of PNG (17); all children were treated to clear parasitemia 
at enrolment and then monitored by active surveillance for parasitemia 
and clinical malaria over 6 months of follow-up. The prevalence of 
IgM and IgG reactivity to the merozoite surface was very high at 
enrolment (90 and 99.5%, respectively; table S4). Both IgM and IgG 
levels were associated with age, such that older children had signifi-
cantly higher IgM and IgG levels than younger children, consistent 
with acquisition of both antibody isotypes with increased cumulative 
exposure among older children (Fig. 5A and table S4). Both IgM 
and IgG were also higher in children who were parasitemic at the 
time of sample collection compared to uninfected children, suggesting 
that both antibody isotypes are boosted during infection (Fig. 5B). 
IgM and IgG levels were moderately positively correlated, suggesting 
co-acquisition of isotypes to some extent (Spearman’s rho = 0.534, 
P < 0.001; Fig. 5C).
Children with high levels of IgM at enrolment were associated 
with a 53% [95% confidence interval (CI), 0.25 to 0.89] reduction in 
the risk of clinical malaria (fever plus >5000 parasites/l) compared 
to children with low levels of IgM after adjusting for confounders 
(age and location of residence) (Table 1 and Fig. 5D). For comparison, 
children with high levels of IgG at enrolment were associated with a 
70% (95% CI, 0.14 to 0.64) reduction in the risk of clinical malaria 
(Table 1 and Fig. 5E). The magnitude of the risk reduction associated 
with high IgM and high IgG was less than seen for the previously 
reported protective effect of complement-fixing activity of antibodies 
within the same children [85% reduced risk of clinical malaria (14)]. 
This suggests that it is the functional capacity of antibodies to fix 
complement that is most strongly linked with protection, rather 
than the magnitude of specific antibody isotypes, and complement 
fixation can be mediated by IgG and IgM.
In complementary analysis, children who had at least one recorded 
infection in follow up (N = 190) were classified as either protected 
from clinical malaria (always asymptomatic when infected) or sus-
ceptible to clinical malaria (experiencing one or more clinical ma-
laria episodes); children with no recorded infections were excluded 
to ensure that only children who were exposed were included in the 
analysis. Children who were protected had significantly higher levels 
of IgM than susceptible children (Fig. 5F). IgG levels were also higher 
in children who were protected. These associations remained signifi-
cant in logistic regression models (adjusted for age and location of 
residence); high levels of IgM were associated with 73% reduced odds 
of susceptibility, and IgG was associated with 77% reduced odds of 
susceptibility. These protective associations were somewhat lower 
than that observed for high C1q-fixing antibodies, as measured pre-
viously (14), which were associated with an 89% reduced odds of 
susceptibility (table S5), further supporting a concept that functional 
activity is the main determinant of protection, and this activity is 
mediated by both IgG and IgM.
DISCUSSION
Antibodies that target the P. falciparum merozoite and prevent blood- 
stage infection are key mediators of protective immunity. However, 
studies have largely focused on understanding IgG responses. The 
dynamics of IgM induction and maintenance and its functional 
 activity that could contribute to protection have not been established. 
Here, we show that IgM was rapidly induced during a primary low-
dose P. falciparum infection of malaria-naïve adults and appeared 
to be prominent in most patients with clinical malaria in individuals 
with life-long malaria exposure, including adults. Contrary to the 
expectation that IgM is a short-lived response to primary infection, 
we found that IgM responses persisted after infection with no apparent 
difference in antibody decay rates between IgM and IgG in Kenyan 
children or following a primary malaria infection acquired in Australian 
travelers. Providing a mechanistic link between IgM and immunity, 
we found that IgM inhibited merozoite invasion in a complement- 
dependent manner and demonstrated the fixation of complement 
to the merozoite surface by IgM. Notably, IgM was markedly more 
effective at activation of complement on the merozoite surface than 
IgG. Consistent with a potential role for IgM in contributing to pro-
tective immunity, merozoite-specific IgM increased with age and was 
associated with reduced risk of clinical malaria in a longitudinal 
cohort study. Overall, our data provide substantive new evidence 
supporting IgM as an important functional antibody that targets 
merozoites and may be a significant contributor to naturally acquired 
protective immunity to malaria. We demonstrate that IgM is a sub-
stantial component of antibody responses to malaria even among 
those with extensive prior malaria exposure and that IgM persists 
following acute infection. This suggests a rethink of the existing 
paradigm of early IgM induction followed by replacement of the IgM 
response with IgG.
We showed that the kinetics of acquisition and decay of naturally 
acquired merozoite-specific IgM and IgG were not apparently dif-
ferent in multiple cohorts. This is despite there being differences in 
the estimated circulating half-lives of each antibody type, suggesting 
that, during acute infection and convalescence, detected antibodies 
result from continued production by short- or long-lived antibody- 
secreting cells [approximate half-lives, 36 days (IgG1) and 28 days 
(IgG3) (18) compared to 5 days (IgM) (19)]. Long-term maintenance 
of IgM was detected in children living in Kenya during a period of 
low malaria transmission in the absence of detected infection. Magni-
tudes of IgM showed no changes within these children, while there 
was evidence of declining IgG. Supporting these findings, in travelers 
returning to Australia from malaria-endemic areas, IgM was detected 
in all individuals longer than 6 months after malaria infection. Study-
ing these subjects allowed us to exclude the possible boosting or re- 
emergence of IgM due to reinfection. Together, results suggest that 
there is induction and maintenance of long-lived IgM-secreting cells 
and/or memory IgM+ B cells following clinical malaria.
Consistent with these findings, Plasmodium-specific somatically 
hypermutated memory IgM+ B cells were recently detected in mouse 
models of malaria and in humans from regions of natural malaria 
transmission (10). Further, using immune repertoire sequencing, it was 
demonstrated that IgM memory B cells can maintain IgM expression 
after an acute malaria episode in young Malian infants (20), although 
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Fig. 5. Association between IgM and IgG levels to the merozoite and malaria risk. IgM and IgG levels to the merozoite surface were measured in plasma from a cohort 
of 199 children in PNG. (A) IgM and IgG were higher in older children (>9 years, n = 109). (B) High IgM and IgG binding were higher in children with concurrent P. falciparum 
infection (n = 134) than in uninfected children, as determined by PCR. (C) Correlation between IgM and IgG among children (Spearman rho and P) is indicated. (D to G) Children 
were stratified into three equal-sized groups based on tertiles according to low (including those classified as “negative”), medium, or high IgM and IgG responders, as 
determined by OD values for each sample. (D and E) High IgM and IgG binding to the merozoite was strongly associated with reduced risk of clinical malaria episodes. (F) Children 
who had at least one infection during the follow-up period (n = 190) were allocated into group defined as protected (always asymptomatic; n = 112) or susceptible (expe-
riencing at least one malaria episode; n = 78) in follow up. P values calculated by Wilcoxon rank sum between groups are indicated.
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the kinetics and functions of IgM were not defined. In a mouse 
model using a rodent Plasmodium species, somatically hypermutated 
memory IgM+ B cells were essential in the generation of both IgM- 
and IgG-secreting plasmablasts during secondary infection (10). This 
finding indicates that IgM responses may have essential roles not only 
directly, due to IgM secretion, but also in maintaining and boosting 
IgG responses. However, the concepts of sustained maintenance 
of circulating IgM antibodies in human immunity, and its presence 
even among those with extensive prior malaria exposure, have not 
been previously established. While we have indirectly shown that 
IgM antibodies measured here are from memory B cells, our data are 
suggestive of IgM memory acquisition; in our cohort of PNG children, 
from an area of relatively high malaria transmission intensity, older 
children who have had greater overall malaria exposure had both 
higher merozoite-specific IgM and IgG levels compared to younger 
children, consistent with the acquisition of both memory antibody 
isotypes with increasing immunity. Thus, in contrast to other patho-
gens (4, 5, 21), anti-malaria IgM not only is a feature of primary 
infection that is subsequently replaced by IgG but also increases as 
immunity is acquired. Recent findings have also shown that IgM 
increases with age against the important sporozoite antigen and 
vaccine target CSP (circumsporozoite protein) (22). Further studies 
are required to specifically investigate the induction of IgM memory 
responses and how they contribute to the increased magnitudes of 
parasite-specific IgM observed with increasing age and parasite exposure. 
Detailed studies of IgM responses before and after repeat malaria 
episodes in longitudinal cohort studies may also help determine the 
significance of IgM memory. Further studies on the roles of IgM 
responses against multiple stages of the P. falciparum life cycle are 
also warranted, especially because antibody complement fixation 
appears to be important for immunity against sporozoites (22) and 
gametes (23).
Merozoite-specific IgM blocked merozoite invasion of RBCs in 
a complement-dependent mechanism, which has been previously 
reported only for IgG (14). Complement activation was via the clas-
sical complement cascade, with the first component of the classical 
cascade C1q, along with downstream components C3 and C5b-C9 
detected on both intact merozoites and recombinant MSP2; com-
plement fixation by antibodies was absent when using C1q-depleted 
sera rather than normal serum. The capacity of IgM to activate 
complement leading to C5b-C9 and merozoite lysis was substan-
tially higher than IgG at similar concentrations; IgM led to much 
higher C5b-C9 formation relative to the fixation of C1q. Among 
these malaria-exposed samples, IgM had a relatively lower avidity 
than IgG in tested samples but still had similar or superior com-
plement-activating activity. This suggests that the acquired IgM 
and IgG have antibody affinities that are above a threshold re-
quired for complement activation. In related studies, we found 
that antibody affinity does not correlate with complement fixation 
activity, probably because antibody avidities are well above the 
threshold required to fix and activate complement (16). IgM has 
been estimated to trigger a complement response that is many-fold 
more effective than IgG (24). This greater activity of IgM further 
highlights the potential importance of IgM in immunity and the 
need for further studies to investigate IgM responses in malaria 
vaccine development. This is the first study to identify a direct 
functional mechanism of naturally acquired human IgM in targeting 
P. falciparum blood-stage replication. It has been also previously 
reported that IgM in the presence of mononuclear cells is able to 
prevent parasite growth in vitro (25). While IgM does not bind to clas-
sical FcR, IgM has been reported to mediate phagocytosis via Fc/R 
(26) and complement receptor 3 (27), and the IgM receptor FcR has 
been reported to be expressed on human activated macrophages and 
circulating monocytes (28), suggesting additional roles for IgM in 
immunity to malaria that should be investigated in future studies.
Supporting a potential role of IgM in contributing to parasite 
clearance and protection, we found that high levels of merozoite- 
specific IgM were associated with protection from clinical malaria in 
a cohort of naturally exposed children from PNG (17). This protective 
association was comparable to that observed for high IgG, but both 
IgM and IgG protective associations were lower than that previously 
reported for C1q-fixing antibodies in the same cohort (14). This might 
suggest that both IgG and IgM mediate complement fixation that 
contributes mechanistically to protection from malaria. IgM responses 
to some merozoite antigens have been also associated with protec-
tion in some longitudinal studies in humans (7–9), but IgM responses 
to whole merozoites have not been previously reported. Because of 
the difficulties in quantifying the magnitude of parasite- specific IgG 
and IgM in individuals, we are unable to directly assess the relative 
importance of each isotype in complement fixation in our cohorts. 
C1q-fixing antibodies were strongly associated with both IgM and 
IgG1 and IgG3 subclasses, and we are not able to assess which anti-
body isotype contributes more significantly to complement fixation 
and protection in vivo. However, IgM appeared to be important in 
mediating complement fixation in a proportion of individuals who 
had low levels of IgG1 and IgG3. Further, serum IgM preparations 
following the removal of IgG effectively fixed complement on mero-
zoites and inhibited invasion in vitro. Together, results suggest that 
it may be the overall capacity of antibodies to mediate complement 
fixation to the parasite, rather than specific IgM or IgG isotypes that 
is required for protection. Further studies in additional populations 
will help define the relative importance of IgM, IgG, and complement 
fixation in immunity.
Avidity was higher for IgM than IgG in controlled human malaria 
infection studies where subjects experienced their first malaria infec-
tion, whereas IgG avidity was higher in residents of Sabah, reflecting 
affinity maturation from repeated malaria exposure and over time. 
Table 1. Association between IgM and IgG to the merozoite surface 
and risk of clinical malaria. The cohort (n = 199) was stratified into three 
equal groups according to low, medium, or high levels (defined by 
tertiles) of IgM to the merozoite surface. Unadjusted hazard ratios (uHRs) 
and HRs adjusted for the predetermined confounders of age and location 
of residence [adjusted HRs (aHRs)] are presented. IgM levels were 
compared between low-versus-medium (LvM) and low-versus-high (LvH) 
groups for the risk of symptomatic malaria (fever plus >5000 parasites/l). 
Calculations were based on the first episode only. 
uHR [95% CI] P aHR [95% CI]age/location P
IgM LvM 0.44 [0.23–0.81] 0.009
0.62 
[0.32–1.18] 0.15
LvH 0.38 [0.20–0.81] 0.002
0.47 
[0.25–0.89] 0.02
IgG LvM 0.51 [0.29–0.91] 0.021
0.58 
[0.32–1.06] 0.08
LvH 0.24 [0.12–0.49] <0.001
0.3 
[0.14–0.64] 0.002
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This difference in avidity did not appear to be important for com-
plement fixation, suggesting that affinity maturation of IgG responses 
may be important for other reasons, such as B cell selection or possibly 
Fc receptor interactions. It is possible that IgM affinity maturation 
also occurs with repeated exposure, but we were not able to directly 
assess this. However, our data do suggest that the extent of any affinity 
maturation in IgM is less than seen for IgG responses to malaria. In 
contrast to antigen-specific IgM responses studied here, a prior study 
reported that nonimmune IgM can bind to merozoite surface antigens 
DBLMSP1 and DBLMSP2 (29). In our studies, we found only low 
levels of reactivity of nonimmune IgM to merozoites compared to 
high reactivity of malaria-specific IgM to merozoites.
Currently, the functional roles and kinetics of IgM responses 
have been largely undefined and IgM has had limited research focus. 
This may partly be because IgM is regarded largely as a feature of 
primary infections based on studies with other pathogens; however, 
we showed that that is not that case in P. falciparum malaria. Fur-
thermore, the role of antibody-complement interactions in immunity 
to merozoites and methods to study these have been only recently 
established, and our studies here demonstrate that this is an important 
mechanism of IgM responses. Therefore, these new insights and ap-
proaches provide avenues for future research into IgM in malaria 
and may facilitate an enhanced focus on this response. Our findings 
also prompt questions regarding why IgM is produced in response 
to malaria and why  responses persist even in those with extensive 
malaria exposure. An early IgM response to primary infection may 
be important because it has high avidity, owing to its pentameric 
structure, and it is a potent activator of complement. Therefore, early 
generation of specific IgM that can fix and activate complement may 
be important until high- affinity IgG response evolves. We speculate 
that IgM responses may continue to be a feature of immune re-
sponses to subsequent malaria episodes because of its strong ability 
to activate complement, which appears to be an important contribu-
tor to immunity (14, 16, 22). The limitation of IgM is that it does not 
interact with Fc receptors, and therefore, the evolution of high- 
affinity IgG is also crucial given its multiple functional activities. The 
findings that both IgG and IgM are prominent in immune individuals 
in different populations and that both isotypes have functional activity 
suggest that a balance of IgG and IgM responses may be important for 
providing effective immunity and preventing disease pathogenesis.
Our findings suggest that the role IgM in human malarial immunity 
needs greater attention and investigation in future studies of naturally 
acquired immunity and vaccine trials. Because of the co-acquisition 
of both IgG and IgM in human immunity to malaria, it is difficult to 
quantify the relative contribution of each antibody isotype to pro-
tective immunity to malaria. Future large longitudinal cohorts with 
repeated measures of antibody acquisition may shed light on these 
outstanding questions, and animal models may also be helpful in 
understanding the in vivo roles of IgM, IgG, and complement. Mouse 
models of malaria are widely used in malaria vaccine research; however, 
mouse strains currently used in these models have very low comple-
ment activity compared to humans (30), which limits the use of these 
for assessment of IgM, IgG, and complement in immunity. In addi-
tion, many P. falciparum merozoite antigens that are important tar-
gets of human immunity are not present in rodent malaria species (3). 
Therefore, investment in the development of new animal models is 
needed.
In summary, we present epidemiological evidence to show that 
IgM is rapidly induced following infection experimentally or by 
natural exposure and is maintained to a level similar to IgG following 
treatment. We showed that merozoite-specific IgM is an important 
part of the immune response to malaria in children and adults. IgM func-
tions by preventing merozoite invasion of RBCs in a complement- 
dependent manner and is a potent activator of complement on the 
merozoite surface. In a cohort of naturally exposed PNG children, 
IgM was associated with protection from clinical malaria. Collectively, 
these findings change our understanding of the role and kinetics of IgM 
in malaria immunity, suggesting an important role of anti- malarial 
IgM in humoral immunity that could be considered in vaccine design.
MATERIALS AND METHODS
Study cohorts
Controlled human malaria infection participants
For participants in controlled human malaria infection, inoculum 
preparation, volunteer recruitment, infection, monitoring, and treatment 
were performed as previously described (31). Briefly, healthy malaria- 
naïve individuals underwent induced blood-stage malaria inoculation 
with 1800 or 2800 viable P. falciparum 3D7-parasitized RBCs, and 
peripheral parasitemia was measured at least daily by quantitative 
polymerase chain reaction (PCR). Participants were treated with anti- 
malarial drugs at day 7 or 8 of infection. Blood samples from 60 volunteers 
(from 10 independent cohorts) were collected before infection (day 0), 
at peak infection (day 7 or 8), and 14 or 15 and 28 to 36 days after 
inoculation; in analysis, these time points are grouped as days 0, 7, 14, 
and 30. Plasma was collected from lithium heparin whole-blood 
samples according to standard procedures, snap frozen in dry ice, 
and stored at −70°C. All studies were registered with the Australian 
and New Zealand Clinical Trial Registration scheme. Participants 
were healthy males and females between 18 and 55 years with no 
prior exposures to malaria or residence in malaria- endemic regions. 
Two groups of participants were tested. The first group (inoculated 
with 2800 viable P. falciparum 3D7-parasitized RBCs; n = 40) 
were drawn from clinical trials nos. NCT02867059, NCT02783833, 
NCT02431637, and NCT02431650. The second group (inoculated 
with 1800 viable P. falciparum 3D7- parasitized RBCs; n = 20), tested 
only on days 0 and 30, was drawn from clinical trial nos. NCT02453581, 
ACTRN12613001040752, and ACTRN12613000565741.
Australian returned traveler
Serum samples were collected from travelers aged 19 to 56 who had 
returned to Australia from malaria-endemic regions and presented 
to hospital with malaria. All patients had no previous malaria epi-
sodes (self-reported). Sera were collected within a week of presenta-
tion and at one or two additional time points following treatment 
(30 to 90 days and > 90 days).
Ngerenya (Kilifi district, Kenya)
Sera samples were collected from venous blood from participants in 
a cohort study conducted in Ngerenya (Kilifi district, Kenya), where 
biannual malaria transmission occurs (May to July and November 
to December). This cohort composed of approximately 300 chil-
dren aged 0.5 to 10 years who were followed for 3 years from May 
2002 to October 2004. Venous blood was collected in May and October 
from each year. At each time point, the presence of P. falciparum 
parasitemia was assessed among all children by light microscopy of 
blood smears. Throughout the cohort period, active malaria case 
detection was performed weekly; children who were febrile (tem-
perature of ≥37.5°C) or had a recent history of fever or illness had a 
blood smear performed. For the purpose of this study, we assessed 
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antibody responses during the period of minimal malaria transmis-
sion, only in children (n = 50) who were sampled at all three time 
points that corresponded to the decline in malaria prevalence (October 
2003, May 2004, and October 2004), who were aparasitemic at all 
time points and intervals, and who were previously positive for anti-
bodies to merozoite antigens at October 2003 (13).
Malaysian clinical malaria studies
For patients with clinical P. falciparum malaria from Sabah, Malaysia, 
plasma samples were collected from participants in prospective 
comparative studies of Plasmodium knowlesi, P. falciparum, and 
Plasmodium vivax malaria, including at three district hospital sites 
(Kudat, Kota Marudu, and Pitas) (18) and a tertiary referral center 
(Queen Elizabeth Hospital, Kota Kinabalu) (32). In adults, this cohort 
has a high proportion of infected males across all species, possibly 
because of infection risk of forest workers (33). Patients who were 
positive for Plasmodium species confirmed by microscopy and PCR, 
who had a fever at the time of presentation or a history of fever in 
the preceding 24 hours, and who provided consent, were enrolled 
The ages of participants included in this analysis were 3 to 55 years. 
Individuals who had been living in the area in the preceding 3 weeks, 
who were negative for Plasmodium spp. by microscopy and PCR, 
and who had no history of fever in previous 48 hours were enrolled 
as endemic healthy controls. Plasma was collected from lithium- 
heparin collection tubes at the time of presentation and follow-up 
visits at days 7, 14, and 28 after anti-malarial drug treatment. For 
this study, all participants with a P. falciparum mono-infection 
(not mixed with other Plasmodium spp. by PCR), and available sera 
samples were analyzed.
PNG children longitudinal (Mugil) cohort
For the longitudinal study of PNG children, plasma samples were 
obtained at enrolment from a prospective treatment reinfection 
cohort of 206 children aged 5 to 14 years (median = 9.3) in Madang, 
PNG (17). For the purpose of this study, 200 children were tested on 
the basis of sample availability. Children were actively reviewed 
every 2 weeks for symptomatic illness and parasitemia and for pas-
sive case detection over a period of 6 months. A clinical episode of 
P. falciparum malaria was defined as a fever and P. falciparum par-
asitemia of >5000 parasites/l.
Purification of IgG and IgM fractions
Pooled plasma from individuals from Sabah who had a recent 
malaria infection (n = 20) or from Australian residents supplied from 
Australian Red Cross blood bank (n = 15) were used for to generate 
IgG and IgM serum fractions. Antibodies were purified from pooled 
plasma via ammonium sulfate precipitation. Plasma was diluted 
to 20% in 0.9% NaCl (w/v), and saturated ammonium sulfate solution 
was added to a final concentration of 50% and incubated on ice 
for 30 min. Precipitate was pelleted at 10,000g and washed once 
with 50% ammonium sulfate solution before being resuspended in 
phosphate- buffered saline (PBS). Samples were dialyzed in PBS in 
dialysis tubing of 14-kDa molecular weight cutoff.
IgG and IgM fractions were separated by the 5-ml NAb Protein 
G Spin Column (Thermo Fisher Scientific) as per the manufacturer’s 
instructions. Ammonium sulfate–precipitated antibodies were incubated 
with columns for 10 min to bind IgG. Unbound supernatants, depleted 
of IgG but containing IgM, were collected; this IgG-depleted fraction 
is referred to as “IgM fraction” for clarity of reading. IgG was eluted 
from column with elution buffer and then dialyzed in PBS in dialysis 
tubing. To improve IgG depletion, IgM fraction was passed over the 
NAb Protein G Spin Column a second time before use in assays. 
To assess purity, fractions were run by SDS–polyacrylamide gel 
electrophoresis 4 to 20% polyacrylamide gel (Bio-Rad) in reduc-
ing sample buffer along with ChromPure IgM and IgG standards. 
Gels were visualized with Coomassie staining.
Quantification of IgG and IgM
Total concentrations of IgM and IgG in each fraction were quanti-
fied with ELISA against ChromPure human IgM and IgG standards 
(Jackson ImmunoResearch). Standards and IgM- and IgG-purified 
fractions were coated in serial dilutions in 96-well flat bottom MaxiSorp 
plates (Nunc) at 4°C overnight in coating buffer (0.1 M sodium car-
bonate and 0.1 M sodium bicarbonate). Plates were washed in PBS-
Tween 0.05% three times and blocked with 1% casein in PBS for 2 hours 
at 37°C, and IgG and IgM were detected with goat anti-human IgG 
horseradish peroxidase (HRP; Merck Millipore) and sheep anti- 
human IgM HRP (Chemicon Australia). Binding was detected with 
TMB (3, 3´,5,5´-tetramethylbenzidine) substrate (Sigma-Aldrich), and 
reaction was stopped using 1 M HCl. The optical density was read 
at 450 nm.
P. falciparum parasite culture and merozoite invasion 
and lysis assays
P. falciparum D10-PfGPF isolates (34) were cultured in culture media 
of RPMI-Hepes (pH 7.4) supplemented with hypozanthine (50 g/ml), 
gentamicin (20 g/ml), 25 nM sodium bicarbonate, and 0.5% AlbuMAX 
II (Gibco) or 0.5% human sera in O+ RBCs from malaria-naïve donors 
(Australian Red Cross blood bank). Cultures were incubated in candle 
jars at 37°C. Parasite cultures were synchronized with heparin (Sigma- 
Aldrich) and used for merozoite isolation and invasion assays as 
described (14). Briefly, late-stage trophozoite and schizont cultures 
were purified by a MACS separation system (Miltenyl Biotec) and 
incubated with E64 protease inhibitor at 10 g/ml to prevent schi-
zont rupture. Once merozoite development was complete, mero-
zoites were purified via filtration with 1.2-m syringe filter. Purified 
merozoites were incubated with uninfected RBCs and normal 
(complement active) or heat-inactivated sera (complement inactive) 
at 50% final concentration, as well as IgG or IgM fractions as de-
scribed (14). Invasion occurred for 30 min before cultures were 
washed and returned to standard culture conditions and allowed to 
mature for 40 hours. Cultures were stained with hydroethidine 
(40 g/ml; Molecular Probes) and then counted by flow cytometry 
(Beckman Coulter Gallios). Detailed methods can be found in 
“Methods in Malaria Research” (2013; www.beiresources.org/portals/ 2/
MR4/Methods_In_Malaria_ Research-6th_edition.pdf). Merozoite lysis 
assays were performed as previously described (14). Green fluorescent 
protein–positive (GFP+) merozoites were stained with ethidum bromide 
and incubated with normal sera and IgG and IgM fractions, and the 
counts of GFP+ merozoites were measured by flow cytometry.
Antibody and complement ELISAs
To assess levels of antibody isotypes targeting merozoites, ELISA 
was performed following a standard procedure. Ninety-six–well flat 
bottom MaxiSorp plates (Nunc) were coated with 50 l of merozoites 
(2.5 × 105 merozoites/ml) or 50 l of recombinant antigen (0.5 g/ml) 
in PBS overnight at 4°C.
For ELISAs, the following antigens were used: MSP1-42 (42-kDa 
fragment of MSP1), a gift from C. Long at the National Institutes of 
Health (His-tagged produced in Escherichia coli) (35); MSP2 (3D7 
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allele, full length) and MSP3 [expressed in E. coli as previously described 
(36)]; MSP4 and MSP5 (3D7, expressed in E. coli), a gift from Ross 
Coppel at Monash University, Melbourne, Victoria, Australia (37, 38); 
MSP6 generated as previously described (36); Rh2 [expressed in 
E.coli as previously described (36)]; and EBA175 and EBA181 [ex-
pressed in E.coli as previously described (8)]. For AMA1 (3D7 allele), 
the “ecto” domain (amino acids 25 to 546) was expressed following 
the replacement of the native signal peptide with a tissue plasminogen 
activator signal peptide and 6-His tag and assessment for potential 
glycosylation sites (www.cbs.dtu.dk/services/NetNGlyc/) leading to 
modification at six amino acid residues to prevent potential glyco-
sylation. The PfAMA1 protein sequence was used to generate a 
DNA sequence that was codon-optimized for mammalian expression 
and then synthesized (GeneArt). The synthetic genes were supplied 
in a Puc vector and then cloned into pcDNA 3.1+ using Xho 1 and 
Bam H1 restriction sites. The final plasmid was quantified and used to 
transfect HEK293F FreeStyle cells (Thermo Fisher Scientific) cultured 
and transfected following the manufacturer’s protocols. Expressed pro-
tein was purified by nickel resin columns (Life Technologies) and 
washed with 20 mM imidazole/PBS (Sigma-Aldrich), and bound pro-
teins were eluted in several 1-ml fractions in 500 mM imidazole/ PBS. 
Protein size and purity were confirmed by SDS-PAGE. For all ELISAs, 
plates were washed three times with PBS-Tween 0.05% and blocked 
with 200 l of 1% casein (Sigma-Aldrich) in PBS for 2 hours at 37°C. 
Serum samples (1:250 dilution) or purified IgG or IgM fractions 
were incubated in 0.1% casein in PBS for 2 hours at room temperature. 
For detection of antibody isotypes and subclasses, antibody binding 
was detected with the following antibodies: anti-human IgM (clone 
HP6083), anti-human IgG1 (clone HP6069), anti-human IgG3 
(HP6050; 1:2000) from Invitrogen detected with goat polyclonal 
anti-mouse IgG HRP conjugate (1:2000; Merck Millipore), or goat 
polyclonal anti-human IgG HRP conjugate (1:2000; Invitrogen) for 
1 hour at room temperature. For detection of complement-fixing 
antibodies, following incubation with sera or IgG/IgM fraction sam-
ples, plates were incubated with 10% normal sera or purified C1q 
as a complement source. C1q fixation was detected with rabbit anti- 
C1q antibodies (Dako) and anti-rabbit HRP (Bio-Rad). C3b and 
membrane attack complex formation was detected with anti-human 
iC3b or anti-human SC5b-9 (Quidel) and anti-mouse IgG HRP 
(Merck Millipore). To assess affinity of IgM and IgG, standard ELISAs 
were performed with the addition of a dissociation step of increasing 
concentrations of ammonium thiocynate (in PBS) incubated for 
20 min at room temperature following incubation with serum samples. 
TMB substrate (Sigma-Aldrich) was added for 1 hour at room tem-
perature, and the reaction was stopped using 1 M HCl. The OD was 
read at 450 nm. For ELISA using isolated merozoites, washes were 
done with PBS without Tween to prevent parasite lysis. Standardization 
of the assays was achieved using positive control plasma pools on 
each plate. Background values (wells with no plasma) were subtracted 
from all values of other wells, and positivity was determined as the 
means + 3SDs of the OD from naïve plasma samples (Australian 
residents) included in each assay or for the PNG children longitudinal 
(Mugil) cohort as the upper 95% CI of naïve plasma samples.
Statistics
Analysis of the association of IgM/IgG with protection in cohort 
study was performed with Stata/SE 12.0. Differences in IgM/IgG 
between groups were assessed by Wilcoxon rank sum tests. For assess-
ment of associations between IgM/IgG and protection, subjects were 
stratified into three equal-sized tertile groups according to low (includ-
ing those classified as “negative”), medium, or high IgM and IgG 
responders, as determined by OD values for each sample. This method 
allows for a dose-response relationship to be examined while main-
taining sufficient numbers of participants in each group to maximize 
statistical power. Tertile groups were compared for risk of clinical 
malaria (fever and >5000 parasites/l) or high-density parasitemia 
(>5000 parasites/l) with the Cox proportional hazards model and 
Kaplan-Meier survival analysis, taking into account the first malaria 
episode only. Age and location of residence were included in adjusted 
analysis as these factors were previously identified as potential con-
founders (17). Effect modifications between parameters were inves-
tigated by interaction terms; no significant interactions were identified 
(P < 0.1 in all cases). IgM and IgG were also compared between 
children who were protected (always asymptomatic when infected; 
n = 112) or who were susceptible (had at least one episode of clinical 
malaria; n = 78) during follow up. Logistical regression analysis of 
protected and susceptible outcomes was adjusted for age and location 
of residence. This analysis only considered children who had at least 
one infection during follow-up to ensure that analysis included only 
children who were exposed to infection.
All other statistical analyses were performed in GraphPad Prism. 
Wilcoxon matched-pairs signed-rank test was used for comparisons of 
responses between acute (day 0) and convalescent time points (days 7 
and 28) in matched samples. Mann-Whitney U test was used to com-
pare responses between different populations (acute versus control) 
and for invasion inhibition assays. Spearman’s rank correlation co-
efficient was used to assess correlations between antibody responses 
and C1q fixation. To assess the relationship between C1q and IgM and 
IgG subclasses in Sabah individuals, ELISA OD data were transformed 
into arbitrary units, relative to the highest responder in the cohort.
Study approval
Written informed consent was obtained from all participants or, in 
the case of children <18 years of age, from their parents or guardians 
before inclusion in studies. Ethics approval for the use of human 
samples in the relevant studies was obtained from the Alfred Human 
Research and Ethics Committee for the Burnet Institute (435-10, 
416-10, and 84-13); the Ethics Committee of the Kenya Medical Re-
search Institute (SSC1131); the Medical Research Advisory Committee 
of Papua New Guinea (MRAC 98.03); the Medical Research and 
Ethics Committee, Ministry of Health, Malaysia (NMRR 10 754 6684); 
the Human Ethics Committee of the Northern Territory Department 
of Health and Menzies School of Health Research (HREC 10/1431); 
the Human Research Ethics Committee Melbourne Health (2004.038); 
and the Human Research and Ethics Committee of the QIMR- 
Berghofer Institute of Medical Research (P1479).
SUPPLEMENTARY MATERIALS
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content/full/5/9/eaax4489/DC1
Fig. S1. IgM and IgG antibody induction to individual merozoite antigens following primary  
P. falciparum infection in naïve adults.
Fig. S2. IgM, IgG1, and IgG3 during clinical P. falciparum malaria and following treatment in 
patients from Sabah.
Fig S3. Purification of IgG and IgM fractions.
Fig S4. Merozoite lysis with IgM and IgG fractions.
Fig S5. C1q-fixing antibodies in Sabah individuals.
Table S1. Proportion of responses above positive threshold.
Table S2. Cohort characteristics of patients with clinical malaria from Sabah, Malaysia.
Table S3. Australia resident returned travelers.
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Table S4. Prevalence and levels of IgM and IgG to the merozoite surface in the longitudinal 
cohort of PNG.
Table S5. Associations between IgM, IgG, and C1q to the merozoite surface and odds of 
susceptibility to malaria in PNG children.
REFERENCES AND NOTES
 1. World Health Organization, World Malaria Report 2016, 1–186 (2017).
 2. RTS,S Clinical Trials Partnership, Efficacy and safety of RTS,S/AS01 malaria vaccine with or 
without a booster dose in infants and children in Africa: Final results of a phase 3, 
individually randomised, controlled trial. Lancet 386, 31–45 (2015).
 3. J. G. Beeson, D. R. Drew, M. J. Boyle, G. Feng, F. J. I. Fowkes, J. S. Richards, Merozoite 
surface proteins in red blood cell invasion, immunity and vaccines against malaria.  
FEMS Microbiol. Rev. 40, 343–372 (2016).
 4. M. G. Guzman, S. B. Halstead, H. Artsob, P. Buchy, J. Farrar, D. J. Gubler, E. Hunsperger, 
A. Kroeger, H. S. Margolis, E. Martinéz, M. B. Nathan, J. L. Pelegrino, C. Simmons, S. Yoksan, 
R. W. Peeling, Dengue: A continuing global threat. Nat. Rev. Micro. 8, S7–S16 (2010).
 5. M. P. Busch, S. H. Kleinman, L. H. Tobler, H. T. Kamel, P. J. Norris, I. Walsh, J. L. Matud, 
H. E. Prince, R. S. Lanciotti, D. J. Wright, J. M. Linnen, S. Caglioti, Virus and antibody 
dynamics in acute west nile virus infection. J. Infect. Dis. 198, 984–993 (2008).
 6. G. D. Tomaras, G. D. Tomaras, N. L. Yates, P. Liu, L. Qin, G. G. Fouda, L. L. Chavez, 
A. C. Decamp, R. J. Parks, V. C. Ashley, J. T. Lucas, M. Cohen, J. Eron, C. B. Hicks, H.-X. Liao, 
S. G. Self, G. Landucci, D. N. Forthal, K. J. Weinhold, B. F. Keele, B. H. Hahn, M. L. Greenberg, 
L. Morris, S. S. A. Karim, W. A. Blattner, D. C. Montefiori, G. M. Shaw,  
A. S. Perelson, B. F. Haynes, Initial B-cell responses to transmitted human 
immunodeficiency virus type 1: Virion-binding immunoglobulin M (IgM) and IgG 
antibodies followed by plasma anti-gp41 antibodies with ineffective control of initial 
viremia. J. Virol. 82, 12449–12463 (2008).
 7. D. Dodoo, A. Aikins, K. A. Kusi, H. Lamptey, E. Remarque, P. Milligan, S. Bosomprah, 
R. Chilengi, Y. D. Osei, B. D. Akanmori, M. Theisen, Cohort study of the association 
of antibody levels to AMA1, MSP119, MSP3 and GLURP with protection from clinical 
malaria in Ghanaian children. Malar. J. 7, 142 (2008).
 8. J. S. Richards, D. I. Stanisic, F. J. I. Fowkes, L. Tavul, E. Dabod, J. K. Thompson, S. Kumar, 
C. E. Chitnis, D. L. Narum, P. Michon, P. M. Siba, A. F. Cowman, I. Mueller, J. G. Beeson, 
Association between naturally acquired antibodies to erythrocyte-binding antigens 
of Plasmodium falciparum and protection from malaria and high-density parasitemia. 
Clin. Infect. Dis. 51, e50–e60 (2010).
 9. B. Adu, M. K. Cherif, S. Bosomprah, A. Diarra, F. K. N. Arthur, E. K. Dickson, G. Corradin, 
D. R. Cavanagh, M. Theisen, S. B. Sirima, I. Nebie, D. Dodoo, Antibody levels against GLURP 
R2, MSP1 block 2 hybrid and AS202.11 and the risk of malaria in children living 
in hyperendemic (Burkina Faso) and hypo-endemic (Ghana) areas. Malar. J. 15, 123 (2016).
 10. A. T. Krishnamurty, C. D. Thouvenel, S. Portugal, G. J. Keitany, K. S. Kim, A. Holder, 
P. D. Crompton, D. J. Rawlings, M. Pepper, Somatically hypermutated Plasmodium-
specific IgM+ memory B cells are rapid, plastic, early responders upon malaria 
rechallenge. Immunity 45, 402–414 (2016).
 11. C. R. Engwerda, G. Minigo, F. H. Amante, J. S. McCarthy, Experimentally induced blood 
stage malaria infection as a tool for clinical research. Trends Parasitol. 28, 515–521 
(2012).
 12. J. G. Burel, S. H. Apte, P. L. Groves, M. J. Boyle, C. Langer, J. G. Beeson, J. S. McCarthy, 
D. L. Doolan, Dichotomous miR expression and immune responses following primary 
blood-stage malaria. JCI Insight 2, 93434 (2017).
 13. C. K. Mugyenyi, S. R. Elliott, X. Z. Yap, G. Feng, P. Boeuf, G. Fegan, F. F. H. Osier, 
F. J. I. Fowkes, M. Avril, T. N. Williams, K. Marsh, J. G. Beeson, Declining malaria 
transmission differentially impacts the maintenance of humoral immunity to Plasmodium 
falciparum in children. J. Infect. Dis. 216, 887–898 (2017).
 14. M. J. Boyle, L. Reiling, G. Feng, C. Langer, F. H. Osier, H. Aspeling-Jones, Y. S. Cheng, 
J. Stubbs, K. K. Tetteh, D. J. Conway, J. S. McCarthy, I. Muller, K. Marsh, R. F. Anders, 
J. G. Beeson, Human antibodies fix complement to inhibit Plasmodium falciparum 
invasion of erythrocytes and are associated with protection against malaria. Immunity 42, 
580–590 (2015).
 15. M. J. Boyle, D. W. Wilson, J. S. Richards, D. T. Riglar, K. K. A. Tetteh, D. J. Conway, 
S. A. Ralph, J. Baum, J. G. Beeson, Isolation of viable Plasmodium falciparum merozoites 
to define erythrocyte invasion events and advance vaccine and drug development.  
Proc. Natl. Acad. Sci. U.S.A. 107, 14378–14383 (2010).
 16. L. Reiling, M. J. Boyle, M. T. White, D. W. Wilson, G. Feng, R. Weaver, D. H. Opi, 
K. E. M. Persson, J. S. Richards, P. M. Siba, F. J. I. Fowkes, E. Takashima, T. Tsuboi, 
 I. Mueller, J. G. Beeson, Targets of complement-fixing antibodies in protective immunity 
against malaria in children. Nat. Commun. 10, 610 (2019).
 17. P. Michon, J. L. Cole-Tobian, E. Dabod, S. Schoepflin, J. Igu, M. Susapu, N. Tarongka, 
P. A. Zimmerman, J. C. Reeder, J. G. Beeson, L. Schofield, C. L. King, I. Mueller, The risk 
of malarial infections and disease in Papua New Guinean children. Am. J. Trop. Med. Hyg. 
76, 997–1008 (2007).
 18. M. J. Grigg, T. William, B. E. Barber, G. S. Rajahram, J. Menon, E. Schimann, C. S. Wilkes, 
K. Patel, A. Chandna, R. N. Price, T. W. Yeo, N. M. Anstey, Artemether-lumefantrine versus 
chloroquine for the treatment of uncomplicated Plasmodium knowlesi malaria: 
An open-label randomized controlled trial CAN KNOW. Clin. Infect. Dis. 66, 229–236 
(2018).
 19. M.-A. Alyanakian, E. Bernatowska, J.-M. Scherrmann, P. Aucouturier, J.-L. Poplavsky, 
Pharmacokinetics of total immunoglobulin G and immunoglobulin G subclasses 
in patients undergoing replacement therapy for primary immunodeficiency syndromes. 
Vox Sang. 84, 188–192 (2003).
 20. B. S. Wendel, C. He, M. Qu, D. Wu, S. M. Hernandez, K.-Y. Ma, E. W. Liu, J. Xiao, 
P. D. Crompton, S. K. Pierce, P. Ren, K. Chen, N. Jiang, Accurate immune repertoire 
sequencing reveals malaria infection driven antibody lineage diversification in young 
children. Nat. Commun. 8, 531 (2017).
 21. G. M. Varghese, V. M. Rajagopal, P. Trowbridge, D. Purushothaman, S. J. Martin, Kinetics 
of IgM and IgG antibodies after scrub typhus infection and the clinical implications.  
Int. J. Infect. Dis. 71, 53–55 (2018).
 22. L. Kurtovic, M. C. Behet, G. Feng, L. Reiling, K. Chelimo, A. E. Dent, I. Mueller, J. W. Kazura, 
R. W. Sauerwein, F. J. I. Fowkes, J. G. Beeson, Human antibodies activate complement 
against Plasmodium falciparum sporozoites, and are associated with protection against 
malaria in children. BMC Med. 16, 61 (2018).
 23. D. Read, A. H. Lensen, S. Begarnie, S. Haley, A. Raza, R. Carter, Transmission-blocking 
antibodies against multiple, non-variant target epitopes of the Plasmodium falciparum 
gamete surface antigen Pfs230 are all complement-fixing. Parasite Immunol. 16, 511–519 
(1994).
 24. N. R. Cooper, The classical complement pathway: Activation and regulation of the first 
complement component. Adv. Immunol. 37, 151–216 (1985).
 25. J. Brown, B. M. Greenwood, R. J. Terry, Cellular mechanisms involved in recovery 
from acute malaria in Gambian children. Parasite Immunol. 8, 551–564 (1986).
 26. A. Shibuya, N. Sakamoto, Y. Shimizu, K. Shibuya, M. Osawa, T. Hiroyama, H. J. Eyre, 
G. R. Sutherland, Y. Endo, T. Fujita, T. Miyabayashi, S. Sakano, T. Tsuji, E. Nakayama, 
J. H. Phillips, L. L. Lanier, H. Nakauchi, Fc/ receptor mediates endocytosis of IgM-coated 
microbes. Nat. Immunol. 1, 441–446 (2000).
 27. J. R. Weinstein, Y. Quan, J. F. Hanson, L. Colonna, M. Iorga, S.-i. Honda, K. Shibuya, 
A. Shibuya, K. B. Elkon, T. Möller, IgM-dependent phagocytosis in microglia is mediated 
by complement receptor 3, not Fc/ receptor. J. Immunol. 195, 5309–5317 (2015).
 28. A. Sigruener, C. Buechler, S. M. Bared, M. Grandl, C. Aslanidis, P. Ugocsai, 
 M. Gehrmann, G. Schmitz, E-LDL upregulates TOSO expression and enhances the survival 
of human macrophages. Biochem. Biophys. Res. Commun. 359, 723–728 (2007).
 29. C. Crosnier, Z. Iqbal, E. Knuepfer, S. Maciuca, A. J. Perrin, G. Kamuyu, D. Goulding, 
L. Y. Bustamante, A. Miles, S. C. Moore, G. Dougan, A. A. Holder, D. P. Kwiatkowski, 
J. C. Rayner, R. J. Pleass, G. J. Wright, Binding of Plasmodium falciparum merozoite surface 
proteins DBLMSP and DBLMSP2 to human immunoglobulin M is conserved among 
broadly diverged sequence variants. J. Biol. Chem. 291, 14285–14299 (2016).
 30. G. L. Ong, M. J. Mattes, Mouse strains with typical mammalian levels of complement 
activity. J. Immunol. Methods 125, 147–158 (1989).
 31. J. S. McCarthy, S. Sekuloski, P. M. Griffin, S. Elliott, N. Douglas, C. Peatey,  
R. Rockett, P. O’Rourke, L. Marquart, C. Hermsen, S. Duparc, J. Möhrle,  
K. R. Trenholme, A. J. Humberstone, A pilot randomised trial of induced blood-stage 
Plasmodium falciparum infections in healthy volunteers for testing efficacy of new 
antimalarial drugs. PLOS ONE 6, e21914 (2011).
 32. B. E. Barber, T. William, M. J. Grigg, J. Menon, S. Auburn, J. Marfurt, N. M. Anstey, T. W. Yeo, 
A prospective comparative study of knowlesi, falciparum, and vivax malaria in Sabah, 
Malaysia: High proportion with severe disease from Plasmodium knowlesi 
and Plasmodium vivax but no mortality with early referral and artesunate therapy.  
Clin. Infect. Dis. 56, 383–397 (2013).
 33. M. J. Grigg, T. William, B. E. Barber, G. S. Rajahram, J. Menon, E. Schimann, K. Piera, 
C. S. Wilkes, K. Patel, A. Chandna, C. J. Drakeley, T. W. Yeo, N. M. Anstey, Age-related 
clinical spectrum of Plasmodium knowlesi malaria and predictors of severity.  
Clin. Infect. Dis. 67, 350–359 (2018).
 34. D. W. Wilson, B. S. Crabb, J. G. Beeson, Development of fluorescent Plasmodium 
falciparum for in vitro growth inhibition assays. Malar. J. 9, 152 (2010).
 35. S. Singh, K. Miura, H. Zhou, O. Muratova, B. Keegan, A. Miles, L. B. Martin, A. J. Saul, 
L. H. Miller, C. A. Long, Immunity to recombinant plasmodium falciparum merozoite 
surface protein 1 (MSP1): Protection in Aotus nancymai monkeys strongly correlates 
with anti-MSP1 antibody titer and in vitro parasite-inhibitory activity. Infect. Immun. 74, 
4573–4580 (2006).
 36. L. Reiling, J. S. Richards, F. J. I. Fowkes, A. E. Barry, T. Triglia, W. Chokejindachai, P. Michon, 
L. Tavul, P. M. Siba, A. F. Cowman, I. Mueller, J. G. Beeson, Evidence that the erythrocyte 
invasion ligand PfRh2 is a target of protective immunity against Plasmodium falciparum malaria. 
J. Immunol. 185, 6157–6167 (2010).
 37. L. Wang, C. G. Black, V. M. Marshall, R. L. Coppel, Structural and antigenic properties 
of merozoite surface protein 4 of Plasmodium falciparum. Infect. Immun. 67, 2193–2200 (1999).
 o
n
 April 14, 2020
http://advances.sciencem
ag.org/
D
ow
nloaded from
 
Boyle et al., Sci. Adv. 2019; 5 : eaax4489     25 September 2019
S C I E N C E  A D V A N C E S  |  R E S E A R C H  A R T I C L E
14 of 14
 38. V. M. Marshall, A. Silva, M. Foley, S. Cranmer, L. Wang, D. J. McColl, D. J. Kemp, R. L. Coppel, 
A second merozoite surface protein (MSP-4) of Plasmodium falciparum that contains 
an epidermal growth factor-like domain. Infect. Immun. 65, 4460–4467 (1997).
Acknowledgments: RBC and human serum used for parasite culture and naïve controls were 
provided by the Australian Red Cross blood bank (Melbourne and Darwin). We thank 
J. Richards for assistance with collating returned traveler samples, all participants and parents 
or guardians involved in the clinical studies, and the staff of the Papua New Guinea Institute 
for Medical Research, along with Malaysian Ministry of Health hospital directors and clinical 
staff at Kudat, Kota Marudu, and Pitas district hospitals and at Queen Elizabeth Hospital (Kota 
Kinabalu) and with Kenya Medical Research Institute (Kilifi, Kenya). We would like to thank the 
Director General of Health Malaysia for permission to publish this work. This work is published 
with permission from the director of KEMRI. Funding: This work was supported by the 
National Health and Medical Research Council of Australia (NHMRC) [program grants and 
senior research fellowships to J.G.B., I.M., D.L.D., J.S.M., C.E., and N.M.A.; and project grant, early 
career fellowship to M.J.B. (GTN 1125656) and B.E.B., and career development award to M.J.B. 
(GTN 1141632)]; the Australian Research Council (future fellowships to F.J.I.F.); the Channel 7 
Children’s Research Foundation (grant to M.J.B. and G.M.); the Australian Centre of Research 
Excellence in Malaria Elimination, NHMRC (to N.M.A., J.G.B.,, I.M., J.S.M., and F.J.I.F.); and the 
Wellcome Trust UK (to T.N.W., S.K., K.M., and J.G.B.). The Burnet Institute is supported by the 
NHMRC for Independent Research Institutes Infrastructure Support Scheme and the Victorian 
State Government Operational Infrastructure Support. Author contributions: M.J.B., J.G.B., 
J.A.C., and G.M. designed the research studies. M.J.B., J.A.C., I.H., L.R., G.F., A.H., L.K., and D.O. 
conducted the experiments. M.J.B., J.A.C., I.H., L.R., G.F., and F.J.I.F. analyzed the data. K.A.P., 
B.E.B., M.J.G., D.P.E., D.L.D., D.R.D., F.H.A., F.d.L.R., C.L., T.W., T.N.W., S.K., K.M., C.E., J.S.M., I.M., and 
N.M.A. provided the reagents. M.J.B., J.A.C., I.H., G.M., C.E., and J.G.B. contributed to the 
manuscript preparation with feedback from all other authors. Competing interests: I.M. is an 
inventor on a patent related to this work filed by the Walter and Eliza Hall Institute of Medical 
Research (no. WO2018130871A1 PCT, issued 21 December 2017). All other authors declare 
that they have no competing interests. Data and materials availability: All data needed to 
evaluate the conclusions in the paper are present in the paper and/or the Supplementary 
Materials. Samples from controlled human malaria infection trials can be provided by J.S.M. 
subject to ethical constraints of sample collection and pending scientific review, sample 
availability, and a completed material transfer agreement. Request for samples should be 
submitted to J.S.M. (j.mccarthy@uq.edu.au).
Submitted 25 March 2019
Accepted 3 September 2019
Published 25 September 2019
10.1126/sciadv.aax4489
Citation: M. J. Boyle, J. A. Chan, I. Handayuni, L. Reiling, G. Feng, A. Hilton, L. Kurtovic, D. Oyong, 
K. A. Piera, B. E. Barber, T. William, D. P. Eisen, G. Minigo, C. Langer, D. R. Drew, F. de Labastida Rivera, 
F. H. Amante, T. N. Williams, S. Kinyanjui, K. Marsh, D. L. Doolan, C. Engwerda, F. J. I. Fowkes, 
M. J. Grigg, I. Mueller, J. S. McCarthy, N. M. Anstey, J. G. Beeson, IgM in human immunity to Plasmodium 
falciparum malaria. Sci. Adv. 5, eaax4489 (2019).
 o
n
 April 14, 2020
http://advances.sciencem
ag.org/
D
ow
nloaded from
 
 malariaPlasmodium falciparumIgM in human immunity to 
L. Doolan, C. Engwerda, F. J. I. Fowkes, M. J. Grigg, I. Mueller, J. S. McCarthy, N. M. Anstey and J. G. Beeson
D. P. Eisen, G. Minigo, C. Langer, D. R. Drew, F. de Labastida Rivera, F. H. Amante, T. N. Williams, S. Kinyanjui, K. Marsh, D. 
M. J. Boyle, J. A. Chan, I. Handayuni, L. Reiling, G. Feng, A. Hilton, L. Kurtovic, D. Oyong, K. A. Piera, B. E. Barber, T. William,
DOI: 10.1126/sciadv.aax4489
 (9), eaax4489.5Sci Adv 
ARTICLE TOOLS http://advances.sciencemag.org/content/5/9/eaax4489
MATERIALS
SUPPLEMENTARY http://advances.sciencemag.org/content/suppl/2019/09/23/5.9.eaax4489.DC1
REFERENCES
http://advances.sciencemag.org/content/5/9/eaax4489#BIBL
This article cites 38 articles, 9 of which you can access for free
PERMISSIONS http://www.sciencemag.org/help/reprints-and-permissions
Terms of ServiceUse of this article is subject to the 
 is a registered trademark of AAAS.Science AdvancesYork Avenue NW, Washington, DC 20005. The title 
(ISSN 2375-2548) is published by the American Association for the Advancement of Science, 1200 NewScience Advances 
BY).
Science. No claim to original U.S. Government Works. Distributed under a Creative Commons Attribution License 4.0 (CC 
Copyright © 2018 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of
 o
n
 April 14, 2020
http://advances.sciencem
ag.org/
D
ow
nloaded from
 
